Boston · In-House General Counsel Recruiting
Boston first-GC searches for biotech companies fail when the board hires a listed-company securities lawyer who has never owned a Phase 3 FDA file, then watches the mandate stall through counter-offer season.
Eight Massachusetts biotech IPOs priced around Boston in the first half of 2026, and first general counsel mandates are already stalling on FDA and securities work. Sartori & Partners is highly technical in In-House General Counsel Recruiting work in Boston: we closed 19 such searches over three years. From the ~3500 lawyers we map in Boston, the pool that has already lived a Phase 3 launch is thin. Our mandate telemetry shows 5 of 11 first-GC processes stalled when the hire had never owned a Phase 3 protocol.
01 — The brief answer
Boston recorded eight Massachusetts-headquartered biotech IPOs in the first half of 2026, and the first general counsel searches that followed are stalling on a predictable pair of files. Boards that call biotech general counsel recruiters Boston usually do so after a securities-heavy candidate has already frozen on FDA launch work, or after a commercial-stage chief legal officer has walked away from a pre-revenue mix. Across 250 structured interviews with Boston partners and counsel over 36 months, Sartori found 38% of in-house respondents said their first GC hire failed when the board treated FDA and trial contracting as outside-counsel overflow.
Sartori's Boston files show the same failure mode in live processes. We closed 19 In-House General Counsel Recruiting searches over three years; in 11 closed in-house searches in Boston over 24 months, 5 stalled when the hire had never owned a Phase 3 protocol. One general counsel at a clinical-stage immunology company told us that the board demanded IPO securities fluency and then refused to put FDA correspondence inside the seat. MassBio's August 2026 snapshot recorded $3.45 billion of Massachusetts biopharma venture funding and $18 billion of reported acquisitions in that half — capital that forces a first in-house lawyer to own securities, FDA, and launch compliance together. A late-stage Boston biotech is advertising that first general counsel role in 2026.
Years in this market
8years
Searches closed · 3 yrs
19
Completion rate
94%
Median timeline
4to 7 months
Sartori & Partners trailing record · In-House General Counsel Recruiting · Boston
02 — The bench
The first Boston biotech general counsel owns FDA, securities, and launch files on day one. That is the job, not a later add-on. The live first-GC brief in Boston asks the hire to serve as the first in-house lawyer and board secretary, to build capital-raising and public-company reporting, to run FDA and launch compliance for a lead asset moving toward Phase 3, and to cover clinical-trial, licensing, and collaboration contracts plus IP, employment, and equity-plan counsel. Adjacent feeder seats are commercial-stage chief legal officer roles at Moderna, Vertex, Biogen, and Alnylam; clinical-stage chief legal officer seats at Xilio Therapeutics in Waltham; and general counsel who have taken a company through a Nasdaq listing at Odyssey Therapeutics. A chief legal officer at a commercial-stage RNA company said the first-GC seat dies if the hire cannot run FDA correspondence without a downtown firm on copy.
Our Boston mandate telemetry records a 27% counter-offer incidence and a median 15 working days from offer to acceptance on in-house general counsel files. We have worked in the Boston market for 8 years, for clinical-stage and newly public boards in biotechnology and healthcare. Candidates arriving from a listed-company legal department often reject the equity-heavy mix that a private Phase 3 company can actually fund; that is a failure mode, not a personality clash. Launch compliance work does not wait for a second in-house hire. Head of legal teams at Takeda, Biogen, and Vertex in Cambridge and the Seaport set the competing bid that pulls people off a first-GC shortlist.
03 — Selected engagements
Anonymised mandates from our Boston book — profile, complication and outcome. Select an engagement to open its file.
04 — The local market
Legal headcount is following the IPO window, not the 2025 research cuts. MassBio reported in 2026 that Massachusetts-headquartered biopharmas priced eight IPOs in the first half of 2026, matching the prior two years combined, while those same companies raised $3.45 billion of venture capital and eleven Massachusetts companies were acquired for a reported $18.0 billion. The same 2026 snapshot counted 113,503 Massachusetts biopharma jobs in 2025, down 3.1 percent — the first annual decline in MassBio's 2026 employment series. Capital concentrated later even as research roles fell. A head of talent at a venture-backed oncology platform reported to us that every shortlist collapsed once the compensation committee saw commercial-stage chief legal officer cash against a private Phase 3 budget.
Sartori maps about 3,500 lawyers in Boston. The in-house slice that has already taken a biotech through an IPO, an FDA launch, and a licensing book is a small cut of that map. Named legal departments already in the cluster include Moderna in Cambridge, Vertex in the Seaport, Biogen, Alnylam, and Takeda. Odyssey Therapeutics priced a Boston IPO in May 2026; Parabilis Medicines priced from Cambridge the same half. Boards still hiring a first general counsel are competing with those departments for the same people, while statewide biopharma employment contracted. That is why first-GC mandates fail: the candidate pool that can do both FDA and securities work is already sitting inside commercial legal teams.
Hiring in Boston?
The market intelligence on this page is the same coverage we use to run retained in-house general counsel recruiting mandates in Boston.
05 — Mandates we run
Over the last three years we closed 19 In-House General Counsel Recruiting searches with a 94% completion rate and a median timeline of 4 to 7 months. Sartori's Boston mandate telemetry shows that in 12 closed in-house searches in Boston over 24 months, 9 offers went to lawyers already sitting in Massachusetts in-house seats. Our files show the remaining three offers required a relocation into the Cambridge–Boston–Waltham strip, and two of those processes lost a week to notice-period friction.
Sartori's Boston files show that in 14 closed in-house searches in Boston over 36 months, 4 candidates withdrew after the compensation committee refused a pre-revenue bonus mix. We do not brief FDA and Nasdaq as two later hires; the live Boston posting already combines them.
06 — Compensation
Cambridge commercial chief legal officer cash sits well above clinical-stage bases. Moderna's March 2026 proxy reported that its Cambridge chief legal officer's annual base rose to $857,000 effective March 2025, with 2025 salary actually paid of $852,192, a non-equity incentive of $1,311,210, and a 2025 summary compensation total of $5,397,914. Alnylam's April 2026 proxy reported a Cambridge chief legal officer starting base of $660,000 from 15 September 2025, a 55% target annual incentive, a $350,000 cash sign-on, and a sign-on RSU grant with a $6,000,430 grant-date fair value. Fulcrum Therapeutics, a clinical-stage Cambridge company, filed an employment agreement dated 22 December 2025 setting an annualized chief legal officer base of $472,200 and a target bonus of up to 40% of base.
Sartori cannot see a disclosed cash band on the live Boston first-GC posting; that employer does not publish pay for the seat. Commercial summary tables are not a first-GC band. Our Boston files treat the Fulcrum $472,200 base, bonus eligibility, equity, and notice as the closer public analog for a private Phase 3 company, and the Moderna and Alnylam figures as the competing bid from commercial departments. Boards briefing a first general counsel still need grade, bonus eligibility, equity mix, notice, and benefits in writing. In 10 closed in-house searches in Boston over 24 months, we misjudge how often a commercial-stage chief legal officer will take that mix: 4 approached candidates walked away.
07 — Methodology
Sartori has worked the Boston in-house market for eight years. We close In-House General Counsel Recruiting searches against mandate telemetry — 19 closed files over three years, 94% completion, four-to-seven-month timelines, 27% counter-offer incidence, 15 working days median offer-to-acceptance — and against the Boston interview cohort, plus quarterly surveys running since 2019. Globally Sartori maps nearly 1.5 million lawyer profiles. Public inputs we used include MassBio's August 2026 Industry Snapshot for IPO, venture, acquisition, and employment counts; Moderna's 16 March 2026 proxy and Alnylam's 6 April 2026 proxy for commercial Cambridge chief legal officer pay; and Fulcrum's 22 December 2025 employment agreement for a clinical-stage Cambridge base.
Internal files show where first-GC processes stall; public filings show what commercial departments pay. We do not treat a Summary Compensation Table as a private-company offer. Massachusetts biopharma jobs contracted 3.1% in 2025 while eight IPOs priced in the first half of 2026, so in-house demand is following later-stage capital rather than research headcount. Our own gap is operational: we cannot see inside companies that never brief a search, and five of eleven first-GC processes still stalled on FDA ownership. Boards get both ledgers.
Hiring in Boston?
Whether you are building a team or weighing a move, we listen first. No obligation.
08 — Sources
09 — Questions
Boston has no verified ranking of first general counsel recruiters for biotech. What can be checked is coverage of the market, stated method and the record on closed searches. Sartori & Partners maps roughly 3,500 lawyers in Boston and has worked this market for 8 years. Over the trailing three years we closed 19 in-house general counsel recruiting searches here at a 94% completion rate, with a median timeline of 4 to 7 months. Across 250 structured interviews with Boston partners and counsel over 36 months, Sartori found 38% of in-house respondents said their first GC hire failed when the board treated FDA and trial contracting as outside-counsel overflow. Sartori's Boston files show that in 14 closed in-house searches in Boston over 36 months, 4 candidates withdrew after the compensation committee refused a pre-revenue bonus mix. Cohort definitions, sample windows and method are published in our research programme, and every figure above is drawn from it.
Four to seven months is the typical timeline on our Boston in-house general counsel files. We closed 19 such searches over three years at a 94% completion rate. Counter-offers hit 27% of those in-house processes, and the median offer-to-acceptance window is 15 working days.
Five of eleven first-GC processes in our Boston files stalled when the hire had never owned a Phase 3 FDA protocol. Boards often staff securities first and leave FDA with a firm. Commercial-stage chief legal officer cash then pulls the same people off the shortlist.
The live Boston first-GC brief puts FDA, securities, launch compliance, and board secretary work in one in-house seat. Clinical-trial, licensing, and collaboration contracts sit there too, with IP, employment, and equity-plan counsel. There is no deputy on day one.
Moderna's 2026 proxy reported an $857,000 chief legal officer base; that figure is not a first-GC band. Alnylam disclosed a $660,000 starting base in its April 2026 proxy. Fulcrum's December 2025 agreement set a clinical-stage Cambridge base at $472,200 with a 40% bonus target. The live first-GC posting publishes no range.
Nine of twelve offers in our 24-month Boston in-house set went to lawyers already in Massachusetts. Feeder seats include commercial chief legal officer teams at Moderna, Vertex, Biogen, and Alnylam, plus clinical-stage in-house lawyers in Waltham and Cambridge. Relocations into the strip added time on the remaining three offers.
Related
In-house & general counsel · All services · Locations · Practice areas
